Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Weekly shot helps asians with obesity shed pounds in major trial

NCT ID NCT04998136

Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a weekly injection of semaglutide (2.4 mg) helps Asian adults with obesity (BMI 25 or higher) lose weight. About 150 participants received either the drug or a placebo for 44 weeks, along with diet and exercise advice. The main goal was to see how much weight they lost. The drug is meant to be taken long-term to keep weight off, so it controls the condition rather than curing it.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

150 people

The number who actually took part.

Started

Aug 2022

Finished

Nov 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age above or equal to 18 years at the time of signing informed consent. * BMI at least 25.0 kg/m\^2 at screening. * Both parents of Asian descent. * History of at least one self-reported unsuccessful dietary effort to lose body weight. Exclusion Criteria: * HbA1c at least 48 mmol/mol (6.5%) as measured by the central laboratory at screening. * History of type 1 or type 2 diabetes mellitus. * A self-reported change in body weight above 5 kg (11 lbs) within 90 days before screening irrespective of medical records. * Any participant where a substantial weight loss, in the investigator's opinion, might jeopardise the participant's safety. * Renal impairment with estimated Glomerular Filtration Rate (eGFR) below 15 mL/min/1.73 m\^2 at screening.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity

Contacts and locations

Locations

  • Ajou University Hospital

    Suwon, 16499, South Korea

  • Dongguk University Ilsan Hospital_Gyeonggi-do

    Gyeonggi-do, 10326, South Korea

  • Gachon University Gil Hospital

    Incheon, 405-760, South Korea

  • Hallym University Sacred Heart Hospital

    Gyeonggi-do, 14068, South Korea

  • King Chulalongkorn Memorial Hospital_Bangkok

    Bangkok, 10330, Thailand

  • King Chulalongkorn Memorial Hospital_Endocrinology

    Bangkok, 10330, Thailand

  • King Chulalongkorn Memorial Hospital_Obstetrics&Gynecology

    Bangkok, 10330, Thailand

  • Konyang University Hospital

    Daejeon, 35365, South Korea

  • Maharaj Nakorn Chiang Mai_Hematology and Oncology

    Chiang Mai, 50200, Thailand

  • Obstetrics&Gynecology King Chulalongkorn Memorial Hospital

    Bangkok, 10330, Thailand

  • Ramathibodi Hospital_Nutrition and Biochemical

    Bangkok, 10400, Thailand

  • SMG-SNU Boramae Medical Center

    Seoul, 07061, South Korea

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, 13620, South Korea

  • Siriraj Hospital_Bangkok_1

    Bangkok, 10700, Thailand

  • Siriraj Hospital_Dept Cardio

    Bangkok, 10700, Thailand

  • Siriraj Institute of Clinical Research

    Bangkok, 10700, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.